We rank companies based on fund manager, research analyst and news sentiment
BGLC stock icon

BioNexus Gene Lab Corp Common stock
BGLC

$0.66
1.64%
 

About: BioNexus Gene Lab Corp is an emerging molecular diagnostics company focused on the application of functional genomics to enable early diagnosis and personalized health management. It focuses on developing and marketing safe, effective, and non-invasive blood tests for the early detection of diseases. The company's non-invasive blood tests analyze changes in ribonucleic acid (or RNA) to detect the potentiality of 11 different diseases. These diseases include eight cancers (nasopharyngeal, lung, liver, stomach, breast, cervical, prostate, and colon), two bowel diseases (colitis and Crohn), and osteoarthritis.

Employees: 39

0
Funds holding %
of 6,474 funds
Analysts bullish %
News positive %

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

0.71% less ownership

Funds ownership: 1.15% [Q3] → 0.44% (-0.71%) [Q4]

20% less funds holding

Funds holding: 5 [Q3] → 4 (-1) [Q4]

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

76% less capital invested

Capital invested by funds: $171K [Q3] → $41.9K (-$130K) [Q4]

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Research analyst outlook

We haven’t received any recent analyst ratings for BGLC.

Financial journalist opinion